X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Why state drug importation pilot programs don’t work

By Nick McGee  |    February 8, 2019
Across the country, some states are recirculating failed proposals that would establish state-run prescription medicine importation schemes. Such proposals would allow medicines from foreign...   Read More

Putting 2018 medicine approvals in context

By Andrew Powaleny  |    January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...   Read More

FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies

By Richard Moscicki, M.D.  |    October 16, 2018
The U.S Food and Drug Administration (FDA) plays a critical role in protecting and promoting the health of all Americans. Every day, the FDA does important work to ensure the safety, efficacy and...   Read More

Balancing innovation and competition in the biologics marketplace

By David Korn  |    October 11, 2018
Last month, I presented at the U.S. Food and Drug Administration’s (FDA) Public Hearing on Facilitating Competition and Innovation in the Biological Products Marketplace. The hearing was part of...   Read More

New analysis shows that more medicines worldwide are available to U.S. patients

By Kevin Haninger  |    June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...   Read More

Spending on medicines grew less than one percent in 2017

By Holly Campbell  |    April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...   Read More

Rare Disease Day: Unmet need inspires innovation

By Andrew Powaleny  |    February 28, 2018
Today, we celebrate Rare Disease Day to both reflect on the progress made toward conquering rare diseases and recognize the continued unmet medical need for these devastating, complex conditions.   Read More

Innovation comes in many forms, including new and expanded uses of existing medicines

By Emma Van Hook  |    January 29, 2018
2017 was a record-breaking year for new drug approvals, with the U.S. Food and Drug Administration (FDA) approving 56 new drugs and biologics. But the innovation did not stop there. As the FDA...   Read More

ICYMI: Why 2017 medicine approvals matter

By Andrew Powaleny  |    January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...   Read More

New surveys find payers and providers want more data from biopharmaceutical companies

By Joe Vandigo  |    December 6, 2017
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates